Overview

A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This a phase II and III study whose purpose is to compare how long various treatment regimens can keep the cancer from worsening or coming back in people with serous or p53 abnormal endometrial cancer. The study is divided into three cohorts: Early stage cohort, advanced stage cohort, and exploratory cohort. Each cohort will have different arms to examine different treatment regimens to determine the best regimen for each cohort. The study will enroll participants into the early stage cohort at this time. The early stage cohort will compare the following treatments after standard of care surgery: - Adjuvant chemotherapy with carboplatin and paclitaxel alone - Adjuvant radiation therapy and chemotherapy with cisplatin, followed by chemotherapy with carboplatin and paclitaxel.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Niraparib
Paclitaxel